Molander U, Milsom I, Ekelund P, Mellström D, Eriksson O
Department of Geriatrics, University of Göteborg, Sweden.
Maturitas. 1990 Jun;12(2):113-20. doi: 10.1016/0378-5122(90)90089-o.
The effect of oral oestriol (3 mg/day for 4 weeks followed by 2 mg/day for a further 6 weeks) on the vaginal bacterial flora, vaginal cytology and urogenital symptoms was assessed in a double-blind, placebo-controlled study in 35 women with symptoms of the urogenital oestrogen deficiency syndrome. No significant differences were observed with regard to the occurrence or severity of urogenital symptoms, vaginal pH, karyopyknotic index (KPI) or the baseline results of vaginal bacterial cultures in the 18 patients (mean age 71.6 +/- 1.0 years) treated with oestriol and the 17 women (mean age 72.6 +/- 1.4 years) who received placebo tablets. A decrease in both vaginal pH (P less than 0.001) and the proportion of faecal-type bacteria (P less than 0.05), and an increase in the KPI (P less than 0.01) and the proportion of lactobacilli (P less than 0.001) were recorded after 10 weeks of treatment with oral oestriol. At the end of the following 10 medication-free weeks all of these parameters except vaginal pH had returned to values that were not significantly altered from the corresponding baseline levels. In the patients treated with placebo no significant changes occurred in vaginal pH, KPI or the proportion of lactobacilli in vaginal cultures during the course of this study. Urogenital symptoms improved in both groups after medication (and even after the medication-free period) in relation to the baseline assessment, which reflects the latter's subjective nature.
在一项双盲、安慰剂对照研究中,对35名患有泌尿生殖系统雌激素缺乏综合征症状的女性,评估了口服雌三醇(前4周每天3毫克,随后6周每天2毫克)对阴道细菌菌群、阴道细胞学和泌尿生殖系统症状的影响。接受雌三醇治疗的18名患者(平均年龄71.6±1.0岁)和接受安慰剂片的17名女性(平均年龄72.6±1.4岁)在泌尿生殖系统症状的发生或严重程度、阴道pH值、核固缩指数(KPI)或阴道细菌培养的基线结果方面,未观察到显著差异。口服雌三醇治疗10周后,阴道pH值(P<0.001)和粪便型细菌比例(P<0.05)降低,KPI(P<0.01)和乳酸杆菌比例(P<0.001)增加。在接下来10周的停药期结束时,除阴道pH值外,所有这些参数均恢复到与相应基线水平无显著变化的值。在本研究过程中,接受安慰剂治疗的患者阴道pH值、KPI或阴道培养物中乳酸杆菌比例均未发生显著变化。与基线评估相比,两组患者在用药后(甚至在停药期后)泌尿生殖系统症状均有所改善,这反映了基线评估的主观性。